A strong industrial network
With 8 GMP, US FDA inspected plants in Europe, the United States, Israel and India for commercial production, supported by 2 non-GMP (ISO 9001) plants in France, our customers have access to a strong industrial network of facilities with a high level of quality, safety and environmental compliance.
We manufacture the most demanding molecules
Seqens continutely invests in its production sites to provide the pharmaceutical industry with state-of-the-art equipment combined with cutting-edge technology in organic chemistry associated with proprietary gene shuffling technology for unique biocatalytic routes.
We conduct GMP manufacturing of APIs and intermediates from kilo to multi-ton quantities. Our range of scale and seamless collaboration within our manufacturing sites allow Seqens to accommodate most projects regardless of size and complexity.
High Potent drugs offer a range of benefits over conventional APIs, including high target specificity and fewer side effects. At SEQENS, we provide the full services and capabilities, from toxicology assessment manufacturing of your HPAPIs.